-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Gnmnde/sCnC8WnqBG/nuLeY+brxgNl7Xmh4/kpn+R203XFvn6k31K+wzHufqUCj3 BEli7u5oTzLPRAtzECLLAg== 0001144204-07-034083.txt : 20070628 0001144204-07-034083.hdr.sgml : 20070628 20070628164301 ACCESSION NUMBER: 0001144204-07-034083 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070628 DATE AS OF CHANGE: 20070628 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ORTEC INTERNATIONAL INC CENTRAL INDEX KEY: 0000889992 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 113068704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-47439 FILM NUMBER: 07947353 BUSINESS ADDRESS: STREET 1: 3960 BROADWAY STREET 2: BLDG 28 CITY: NEW YORK STATE: NY ZIP: 10032 BUSINESS PHONE: 7183264698 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Platinum-Montaur Life Sciences, LLC CENTRAL INDEX KEY: 0001404598 IRS NUMBER: 260204840 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 152 WEST 57TH STREET STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 582-2222 MAIL ADDRESS: STREET 1: 152 WEST 57TH STREET STREET 2: 54TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 SC 13G 1 v079702_sc13g.htm Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No __)

Ortec International, Inc.
(Name of Issuer)

Common Stock, par value $0.001 per share
(Title of Class of Securities)

68749B 40 5
(CUSIP Number)

June 18, 2007
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)

 
 
 

CUSIP No. 68749B 40 5
 
           
1  
Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only):
 
Platinum-Montaur Life Sciences, LLC
     
2  
Check the Appropriate Box if a Member of a Group (See Instructions): 
  (a)   o
  (b)   o
     
3   SEC use only:
   
   
     
4  
Citizenship or Place of Organization:
   
 
Delaware
       
  5   Sole Voting Power:
     
Number of  
21,300,000
       
Shares 6   Shared Voting Power:
Beneficially    
Owned by  
0
       
Each 7   Sole Dispositive Power:
Reporting    
Person  
21,300,000
       
With: 8   Shared Dispositive Power:
     
   
0
     
9  
Aggregate Amount Beneficially Owned by Each Reporting Person:
   
 
· 7,100,000 shares underlying 355 shares of Series A Preferred Stock
· 3,550,000 shares underlying Series A Warrants
· 7,100,000 shares underlying Series M Warrants
· 3,550,000 shares underlying Series M-1 Warrants
     
10  
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):
   
  o
     
11   Percent of Class Represented by Amount in Row (9):
   
 
9.999% -- The Certificate of Designations of Series A Preferred Stock provides a limitation on the conversion of such preferred stock such that the number of shares of common stock that may be acquired by the holder upon conversion of the preferred stock shall be limited to the extent necessary to ensure that following such conversion the total number of shares of common stock then beneficially owned by the holder does not exceed 9.99% of the total number of issued and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such conversion). Each of the warrants provides a limitation on the exercise of such warrants such that the number of shares of common stock that may be acquired by the holder upon exercise of the warrants shall be limited to the extent necessary to ensure that following such exercise the total number of shares of common stock then beneficially owned by the holder does not exceed 9.999% of the total number of issued and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such exercise).
     
12   Type of Reporting Person (See Instructions):
   
 
OO
 
 
2
 

Item 1.

Ortec International, Inc.

(b) Address of Issuer's Principal Executive Offices.
3960 Broadway
New York, NY 10032

Item 2.



(b) Address or Principal Business Office or, if none, Residence.

152 West 57th Street, 54th Floor
New York, NY 10019

Delaware

(d) Title of Class of Securities.

Common Stock, par value $0.001 per share
(e) CUSIP No.
68749B 40 5

 
(a)
o Broker or dealer registered under section 15 of the Act.
 
o Bank as defined in Section 3(a)(6) of the Act.
 
o Insurance company as defined in Section 3(a)(19) of the Act.
 
o Investment company registered under section 8 of the Investment Company Act of 1940.
 
o An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
 
o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
 
o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

 
3
 

 
(h)
o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 
o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
 
o Group, in accordance with Rule 13d-1(b)(1)(ii)(J).


 
(a)
Amount Beneficially Owned:

 
·
7,100,000 shares underlying 355 shares of Series A Preferred Stock
 
·
3,550,000 shares underlying Series A Warrants
 
·
7,100,000 shares underlying Series M Warrants
 
·
3,550,000 shares underlying Series M-1 Warrants

The Certificate of Designations of Series A Preferred Stock provides a limitation on the conversion of such preferred stock such that the number of shares of common stock that may be acquired by the holder upon conversion of the preferred stock shall be limited to the extent necessary to ensure that following such conversion the total number of shares of common stock then beneficially owned by the holder does not exceed 9.99% of the total number of issued and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such conversion).

Each of the warrants provides a limitation on the exercise of such warrants such that the number of shares of common stock that may be acquired by the holder upon exercise of the warrants shall be limited to the extent necessary to ensure that following such exercise the total number of shares of common stock then beneficially owned by the holder does not exceed 9.999% of the total number of issued and outstanding shares of common stock (including for such purpose the shares of common stock issuable upon such exercise).

(b) Percent of class: 9.999%
 
(c) Number of shares as to which such person has:
(i)    Sole power to vote or to direct the vote: 21,300,000
(ii)   Shared power to vote or to direct the vote: 0
(iii)  Sole power to dispose or to direct the disposition of: 21,300,000
(iv) Shared power to dispose or to direct the disposition of: 0

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following o.


 
4
 

Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. N/A


If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. N/A


If a group has filed this schedule pursuant to Rule 13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group. N/A


Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. N/A


By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


 
5
 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 28, 2007

PLATINUM-MONTAUR LIFE SCIENCES, LLC

By: /s/ MICHAEL GOLDBERG
Name: Michael Goldberg
Title: Member
 
 
6
 
 -----END PRIVACY-ENHANCED MESSAGE-----